## OMCL: Omnicell, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 4.7% in mid entry zone (3.0-6.0%), top quartile (81st pct) cross-sectional ranking. Short-term MRS_5 (0.8%) confirms momentum alignment. Outperforming sector by 3.2%. Caution: momentum weakening (-5.3% MRS), overbought RSI (72).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($39.83)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Taking Stock of Omnicell (OMCL) After Titan XT Launch: What the New Platform Means for Valuation**
- Source: Simply Wall Street | 20251215T040933 | Somewhat-Bullish | Relevance: 100%
- Omnicell (OMCL) recently launched Titan XT, an automated dispensing platform integrated with its OmniSphere cloud, raising questions about its impact on growth and valuation. The stock has seen strong short-term gains, yet remains at a modest discount to analyst targets, potentially signaling a reevaluation of Omnicell's long-term prospects. While analysts project upside, the company's high P/E ratio suggests significant valuation risk if growth falters.

**2. Omnicell Shares Surge on Robust Earnings and Strategic Product Launch**
- Source: AD HOC NEWS | 20251213T070911 | Bullish | Relevance: 100%
- Omnicell's shares surged due to robust third-quarter 2025 earnings which exceeded market expectations, and the strategic launch of its new "Titan XT" medication dispensing system. Analysts have reinforced a positive outlook with raised price targets, despite the company acknowledging a need to improve long-term profitability. The transition towards recurring SaaS revenue is expected to drive better margins.

**3. Omnicell, Inc. $OMCL Stock Holdings Raised by Liontrust Investment Partners LLP**
- Source: MarketBeat | 20251214T120933 | Neutral | Relevance: 100%
- Liontrust Investment Partners LLP significantly increased its stake in Omnicell, Inc. (NASDAQ:OMCL) during the second quarter, now holding 318,284 shares valued at $9.36 million. The stock, which has high institutional ownership (97.70%), is currently rated as a "Hold" with an average price target of $43.00, though analysts' views vary. Omnicell currently trades around $43.86 with a market cap of $1.97 billion.

**4. Taking Stock of Omnicell (OMCL) After Titan XT Launch: What the New Platform Means for Valuation**
- Source: Simply Wall Street | 20251215T120901 | Somewhat-Bullish | Relevance: 97%
- Omnicell (OMCL) recently launched its Titan XT automated dispensing platform, leading investors to re-evaluate the company's growth prospects and valuation. While the shares have seen recent gains, momentum suggests investors are factoring in future Titan-driven growth, with the stock currently considered modestly undervalued by analysts. However, its high P/E ratio presents valuation risks if growth disappoints or market sentiment shifts.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Benchmark | $50 | $45 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Benchmark | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 7 ($1.16M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 58.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Blackrock Inc.: 17.1% (-2.3%)
- Vanguard Group Inc: 12.5% (-0.4%)
- Dimensional Fund Adv: 5.3% (+9.1%)
- Cadian Capital Manag: 4.7% (+25.9%)
- State Street Corpora: 4.6% (-2.0%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.28 elevated, pricing in significant growth expectations. Forward P/E 23.5x stretched relative to 8% growth. Analyst sentiment positive (1 raises, avg +11%). Insider selling cluster ($1.2M in 90 days), potential headwind. Institutional flow bullish (3 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.0B |
| Beta | 0.83 |
| 52W Range | $22.66 - $47.69 |
| Short Interest | 7.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.28 |
| Forward P/E | 23.5 |
| Current P/E | 25.3 |
| YoY Growth | 7.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 10.0% to 4.7% (-5.3% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (3.0-6.0%), cross-sectional ranking at 81st percentile. MRS_5 at 0.8% confirms short-term momentum alignment. Outperforming sector by 3.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 72, risk of mean reversion. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.68% (CS: 81) | Strong |
| RSI_14 | 71.5 | Overbought |
| MACD Histogram | 0.41 | Bullish |
| vs SMA20 | 1.115x | Above |
| vs SMA50 | 1.239x | Above |
| vs SMA200 | 1.353x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $43.27
- **Stop Loss:** $39.83 (8.0% risk)
- **Target:** $48.43 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 348
- **Position Value:** $15,057.96
- **Portfolio %:** 15.06%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 100% | L2 120% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at moderate levels (16.5) with elevated put/call ratio suggesting cautious positioning, while normal yield curve and stable breadth indicate no systemic stress. Focus on selective opportunities with defensive positioning.*

### Earnings

**Next:** 2026-02-05 (Est: $0.49)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.36 | $0.51 | +40.7% |
| 2025Q2 | $0.27 | $0.45 | +66.7% |
| 2025Q1 | $0.20 | $0.26 | +27.1% |
| 2024Q4 | $0.58 | $0.60 | +2.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*